Company Active LTD

Company profile

Bioxydyn Limited

Bioxydyn - Imaging Biomarker Services

Bioxydyn Limited is a UK company with status active founded in 2009.

CRN
06838431
Founded
2009
Age
17

Overview

Legal name
BIOXYDYN LIMITED
Region
Unknown
Registered address
ST JAMES TOWER
7 CHARLOTTE STREET
MANCHESTER
ENGLAND
M1 4DZ
Insolvency history
No

Latest accounts

Financial period: 1 Dec 2023 to 30 Nov 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
7

Company events

Reference milestones and recent Companies House filing stream events.

7 events
21 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Aug
2026

Accounts due

Accounts Due

Next accounts due date

07 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Nov
2024

Accounts filed

Accounts

Last accounts made up date

06 Nov
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ0MjIwMjAwN2FkaXF6a2N4

Published 06 Nov 2024 12:07

10 Aug
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzMTc4MTQzMmFkaXF6a2N4

Published 10 Aug 2024 08:01

05 Mar
2009

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2013
Funded years
2013, 2019
Age at first award
4 years

Projects

2019 Collaborative R&D Lead participant

Oxygen enhanced lung MRI - towards clinical application

1 Mar 2019 to 31 Mar 2021

Awarded
£68,151
Total cost £97,359

"The lung is poorly served by non-ionising or low-dose imaging technologies. Thoracic CT scanning is the main technique available, but does not permit routine follow-up or longitudinal monitoring because of the unacceptably high radiation dose, especially in children. Bioxydyn Ltd is an imaging services business offering quantitative MRI biomarkers for ph...

2013 GRD Development of Prototype Lead participant

3D functional oxygen-enhanced lung imaging

1 Jun 2013 to 31 Dec 2014

Awarded
£249,989
Total cost £739,395

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, characterized by airflow obstruction to the lungs, interfering with normal breathing. It is one of the most common respiratory diseases and the WHO predicts it to be the 3rd leading cause of death worldwide by 2020. Early clinical diagnosis is critical to prevent further deteri...

Product types

Collaborative R&D GRD Development of Prototype